<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<?xml-stylesheet type="text/xsl" href="QRDbundleToHtml.xsl"?>
<?xml-stylesheet type="text/css" href="QRDbundleToHtml.xsl"?>
<Bundle xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://hl7.org/fhir ../../FHIR/XML/fhir-all-xsd/fhir-all.xsd"
	xmlns="http://hl7.org/fhir">
	<!-- change here 2021-04-09, now a transaction -->
	<type value="transaction"/>
	<!-- could include a bundle level timestamp here
    <timestamp></timestamp> -->
	<!-- one document bundle list, covers all the documents -->
	<entry>
		<fullUrl value="urn:uuid:f239eb55-8a15-4fe1-9331-229921f41610"/>
		<resource>
			<List>
				<status value="current"/>
				<mode value="working"/>
				<!-- repeat per document Bundle -->
				<entry>
					<item>
						<!-- matches fullUrl of the Nth Bundle -->
						<reference value="urn:uuid:5e229d9a-e63e-496b-8166-ea2df203b2e5"/>
					</item>
				</entry>
			</List>
		</resource>
		<request>
			<method value="POST"/>
			<url value="List"/>
		</request>
	</entry>
	<!-- Repeat this per document -->
	<!-- Document 1 = zandip SPC English translation -->
	<entry>
		<fullUrl value="urn:uuid:5e229d9a-e63e-496b-8166-ea2df203b2e5"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
			<Bundle>
				<!-- When PUTing, some servers mandate an id here to match the existing id -->
				<!--id value="${instance.bundle[n].idUuid}"/-->
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="temp-Norway-zandip1-EN"/>
					<!-- ACTION: sort out SPOR access -->
				</identifier>
				<!-- fixed code -->
				<type value="document"/>
				<!-- document bundles must have a date (bdl-10) -->
				<timestamp value="2021-06-05T10:41:00Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:8f708a21-0b80-4d87-a187-afe94df9b5cf"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
						<Composition>
							<!-- images if required within html text of this document -->
							<contained>
								<Binary>
									<id value="zandip10mg"/>
									<!-- example format -->
									<contentType value="image/png"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
									<data
										value="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"
									/>
								</Binary>
							</contained>
							<contained>
								<Binary>
									<id value="zandip20mg"/>
									<!-- example format -->
									<contentType value="image/png"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
									<data
										value="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"
									/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
							<extension
								url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
								<valueReference>
									<reference value="#zandip10mg"/>
								</valueReference>
							</extension>
							<extension
								url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
								<valueReference>
									<reference value="#zandip20mg"/>
								</valueReference>
							</extension>
							<status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="100000155532"/>
									<display value="Summary of Product Characteristics"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="List/548506e8-130d-40c4-8979-6177c0a96a66"/>
								<!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/-->
								<!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
							<!-- mandatory date of the document -->
							<date value="2019-02-14"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations"/>
									<value value="temp-org1"/>
									<!-- ACTION - get real org number -->
								</identifier>
							</author>
							<title value="ANNEX 1 - SUMMARY OF PRODUCT CHARACTERISTICS"/>
							<relatesTo>
								<code value="transforms"/>
								<!-- This is the English Translation of the Original Norwegian SmPC. Relate this to the Norwegian SmPC compostion -->
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
							<section>
								<!-- 1. NAME OF THE MEDICINAL PRODUCT -->
								<title value="1. NAME OF THE MEDICINAL PRODUCT"/>
								<code>
									<coding>
										<!-- sections will all have codes to identify them -->
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="00000021212"/>
										<display value="Name Section"/>
									</coding>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<p>Zanidip 10 mg film-coated tablets</p>
									</div>
								</text>
							</section>
							<section>
								<!-- 2. QUALITATIVE AND QUANTITATIVE COMPOSITION -->
								<title value="2. QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="00000021212"/>
										<display value="Composition"/>
									</coding>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<p>Each film-coated tablet contains 10 mg lercanidipine
											hydrochloride (equivalent to 9.4 mg lercanidipine)</p>
										<br/>
										<p>Excipient with known effect:</p>
										<p>Each film-coated tablet
											contains 30 mg of lactose monohydrate.</p>
										<br/>
										<p>For a complete list of excipients, see section <a
												href="#61"
												>6.1</a></p>
										<!-- ACTION: FINISH LINK -->
									</div>
								</text>
							</section>
							<section>
								<!-- 3. PHARMACEUTICAL FORM -->
								<title value="3. PHARMACEUTICAL FORM"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="00000031313"/>
										<display value="Form"/>
									</coding>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<p>Tablet, film-coated</p>
										<p>Yellow, round, biconvex tablet with a dash on one
											side.</p>
										<br/>
										<img src="#zandip10mg"
											alt="An image of a single Zandip 10 mg tablet"/>
										<br/>
										<br/>
										<img src="#zandip20mg"
											alt="An image of a single Zandip 20 mg tablet"/>
									</div>
								</text>
							</section>
							<section>
								<!-- 4. CLINICAL PARTICULARS -->
								<title value="4. CLINICAL PARTICULARS"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="0000002223333"/>
										<display value="clinical-particulars"/>
									</coding>
								</code>
								<section>
									<!-- 4.1 Therapeutic indications -->
									<title value="4.1 Therapeutic indications"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="00000044444"/>
											<display value="Therapeutic Indications"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Zanidip is indicated in adults for the treatment of
												mild to moderate essential hypertension.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.2 Posology and method of administration -->
									<title value="4.2 Posology and method of administration"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="0000005555"/>
											<display value="Posology"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p style="bold">Dosage</p>
											<p>The recommended dose is 10 mg once daily at least 15
												minutes before a meal. The dose can be increased to
												20 mg,depending on individual response.Dose increase
												should be gradual because it may take up to two
												weeks before the maximum antihypertensive effect is
												reachedachieved. In people where monotherapy does
												not give a satisfactory effect, it may be beneficial
												to combineZanidip with a beta-blocker (atenolol), a
												diuretic (hydrochlorothiazide) or an ACE
												inhibitor(captopril or enalapril).As the
												dose-response curve is steep with a plateau at doses
												between 20-30 mg, it is unlikely thatthe effect is
												increased at higher doses. However, the frequency of
												side effects may increase.</p>
											<br/>
											<p>Older</p>
											<p>Although pharmacokinetic data and clinical experience
												suggest that daily adjustment is not requireddosage,
												caution should be exercised when starting
												treatment.</p>
											<br/>
											<p>Pediatric population</p>
											<p>The safety and efficacy of Zanidip in children up to
												18 years of age have not been established. There is
												noneavailable data.</p>
											<br/>
											<p>Impaired renal or hepatic function</p>
											<p>Caution should be exercised when starting treatment
												in patients with mild to moderate renal or renal
												impairmentliver function. Although commonly
												recommended doses can be tolerated by these
												patients, shoulddose increase to 20 mg daily should
												be done with caution. The antihypertensive effect
												may be enhanced inpatients with hepatic impairment.
												Therefore, dose adjustment should be considered.</p>
											<br/>
											<p>Zanidip is contraindicated in patients with severe
												hepatic impairment or in patients withsevere renal
												impairment (GFR &lt;30 ml / min), including patients
												undergoing dialysis (see section <a href="#XXXXXXX"
												>4.3</a> and <a href="#XXXXXX">4.4</a>).</p>
											<br/>
											<p>Method of administration</p>
											<p>Precautions before handling or administering this
												medicine:</p>
											<ul>
												<li>The treatment should preferably be given in the
												morning, at least 15 minutes before
												breakfast.</li>
												<li>This medicine should not be given with
												grapefruit juice (see section <a href="#XXXXXXX"
												>4.3</a> and <a href="#XXXXXX">4.5</a>).</li>
											</ul>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.3 Contraindications -->
									<title value="4.3 Contraindications"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="0"/>
											<display value="Contraindications"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<ul>
												<li>Hypersensitivity to the active substance or to
												any of the excipients listed in <a href="#XXXX"
												>section 6.1</a>.</li>
												<li>Left ventricular obstruction</li>
												<li>Untreated congestive heart failure.</li>
												<li>Unstable angina pectoris or recent (less than 1
												month) heart attack</li>
												<li>Severe hepatic impairment.</li>
												<li>Severe renal impairment (GFR &lt;30 ml / min),
												including patients undergoing
												surgeryhemodialysis.</li>
												<li>Simultaneous administration of:</li>
												<ul list-style-type="circle">
												<li>strong CYP3A4 inhibitors (see <a
												href="#xxxxxx">section 4.5</a>)</li>
												<li>ciclosporin (see <a href="#xxxxxx">section
												4.5</a>)</li>
												<li>grapefruit or grapefruit juice (see <a
												href="#xxxxxx">section 4.5</a>)</li>
												</ul>
											</ul>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.4 Special warnings and precautions for use -->
									<title value="4.4 Special warnings and precautions for use"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="1"/>
											<display value="special warnings"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Sick sinus syndrome</p>
											<p>Caution should be exercised when using lercanidipine
												in patients with sick sinus syndrome (who have not
												pacemaker).</p>
											<br/>
											<p>Left ventricular dysfunction</p>
											<p>Caution should also be exercised when treating
												patients with impaired left ventricular function,
												even if controlled hemodynamic studies have not
												shown deterioration of ventricular function. </p>
											<br/>
											<p>Ischemic heart disease</p>
											<p>Certain short-acting dihydropyridine derivatives may
												be associated with an increased cardiovascular risk
												in patients patients with ischemic heart disease.
												Although lercanidipine is long-acting, caution
												should be exercised expelled in the treatment of
												these patients. Some dihydropyridines may in rare
												cases lead to precordial pain or angina pectoris.
												Patients with pre-existing angina pectoris may in
												very rare cases cases get attacks with increased
												frequency, duration or severity. Isolated cases of
												myocardial infarction can be observed (see <a
												href="#xxxxx">section 4.8</a>).</p>
											<br/>
											<p>Use in renal or hepatic impairment</p>
											<p>Particular caution should be exercised when
												initiating treatment in patients with mild to
												moderaterenal impairment. Although the usually
												recommended dose, 10 mg daily, can be tolerated, one
												shoulddose increase to 20 mg daily should be done
												with caution.</p>
											<p>The antihypertensive effect may be potentiated in
												patients with moderate hepatic impairment.Therefore,
												dose adjustment should be considered</p>
											<p>Lercanidipine is contraindicated in patients with
												severe hepatic impairment, or in patientswith severe
												renal impairment (GFR &lt;30 ml / min), including
												patients undergoing surgeryhemodialysis (see
												sections <a href="#xxxx">4.2</a> and <a href="#xxxx"
												>4.3</a>).</p>
											<br/>
											<p>Peritoneal dialysis</p>
											<p>Lercanidipine has been associated with the
												development of obscurity in peritoneal dialysate in
												patients whoundergoing peritoneal dialysis. These
												turbidities are due to increased concentrations of
												triglycerides inthe peritoneal fluid. Although the
												mechanism is unknown, the turbidity tends to
												disappear after discontinuation oflerkanidipine. It
												is important to know this relationship as cloudy
												dialysate can be mistakenly perceived asinfectious
												peritonitis with subsequent unnecessary
												hospitalization and empirical administration
												ofantibiotics.</p>
											<br/>
											<p>CYP3A4 inducers</p>
											<p>CYP3A4 inducers such as anticonvulsants (eg
												phenytoin, carbamazepine) and rifampicin may
												reducethe plasma concentration of lercanidipine, and
												thus the effect of lercanidipine may be weaker
												thanexpected (see section <a href="#xxxx"
												>4.5</a>).</p>
											<br/>
											<p>Alcohol</p>
											<p>Alcohol should be avoided during treatment, as
												alcohol may potentiate the effect of
												vasodilatorsantihypertensive (see section <a
												href="#xxxx">4.5</a>).</p>
											<br/>
											<p>Lactose</p>
											<p>This medicine contains lactose. Patients with rare
												hereditary problems ofgalactose intolerance, total
												lactase deficiency or glucose-galactose
												malabsorption should not be taken the drug.</p>
											<br/>
											<p>Pediatric population</p>
											<p>The safety and efficacy of lercanidipine have not
												been established in children.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.5 Interaction with other medicinal products and other forms of interaction -->
									<title
										value="4.5 Interaction with other medicinal products and other forms of interaction"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="2"/>
											<display value="interaction"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p style="font-weight: bold">Contraindications to
												concomitant use</p>
											<p>CYP3A4 inhibitors</p>
											<p>Lercanidipine is metabolised by the CYP3A4 enzyme and
												therefore co-administration of inhibitorsof CYP3A4
												affect the metabolism and elimination of
												lercanidipine. An interaction study with apowerful
												CYP3A4 inhibitor, ketoconazole, showed a significant
												increase in plasma levels of lercanidipine (a15-fold
												increase in AUC and 8-fold increase in C max , of
												eutomeric S-lercanidipine).Administration of
												lercanidipine with CYP3A4 inhibitors (eg
												ketoconazole, itraconazole,ritonavir, erythromycin,
												troleandomycin, clarithromycin) should be avoided
												(see section 4.3).</p>
											<br/>
											<p>Ciclosporin</p>
											<p>Increased plasma concentrations of both lercanidipine
												and ciclosporin have been observed
												concomitantlyadministration. A study of healthy
												volunteers has shown that when ciclosporin was
												administered 3 hours laterintake of lercanidipine,
												plasma levels of lercanidipine were not altered, but
												the AUC of ciclosporin increasedby 27%. However,
												co-administration of lercanidipine and ciclosporin
												has resulted in a 3-fold increaseof plasma levels of
												lercanidipine and a 21% increase in the AUC of
												ciclosporin.Ciclosporin and lercanidipine must not
												be co-administered (see section <a href="#xxxx"
												>4.3</a>).</p>
											<br/>
											<p>Grapefruit or grapefruit juice</p>
											<p>As with other dihydropyridines, lercanidipine is
												sensitive to metabolic inhibition caused byof
												grapefruit or grapefruit juice. This can lead to
												increased systemic availability and increased
												hypotensioneffect. Lercanidipine must not be taken
												with grapefruit or grapefruit juice (see section <a
												href="#xxxx">4.3</a>).</p>
											<br/>
											<p style="font-weight: bold">Concomitant use is not
												recommended</p>
											<p>CYP3A4 inducers</p>
											<p>Co-administration of lercanidipine and CYP3A4
												inducers as antiepileptic drugs (eg
												phenytoin,phenobarbital, carbamazepine) and
												rifampicin should be done with caution, as the
												antihypertensivethe effect may be reduced and blood
												pressure should be monitored more frequently than
												normal (see section <a href="#xxxx">4.4</a>).</p>
											<br/>
											<p>Alcohol</p>
											<p>Alcohol should be avoided as it may potentiate the
												effect of vasodilating antihypertensives (see
												section <a href="#xxxx">4.4</a>).</p>
											<br/>
											<p style="font-weight: bold">Precautions, including dose
												adjustments</p>
											<p>CYP3A4 substrates</p>
											<p>Caution should be exercised when administering
												lercanidipine with other CYP3A4 substrates, such
												asterfenadine, astemizole, class III antiarrhythmics
												such as amiodarone, as well as quinidine and
												sotalol.</p>
											<br/>
											<p>Midazolam</p>
											<p>When a dose of 20 mg lercanidipine was
												co-administered with midazolam orally to elderly
												volunteerssubjects, increased the absorption of
												lercanidipine by approx. 40%, and the rate of
												absorption was reduced(t max was delayed from 1.75
												to 3 hours). The concentration of midazolam did not
												change.</p>
											<p>Metoprolol</p>
											<p>When lercanidipine was co-administered with
												metoprolol, a beta-blocker that mainlyeliminated by
												the liver, the bioavailability of metoprolol was not
												altered, while lercanidipinebioavailability was
												reduced by 50%. This effect may be due to the
												reducedthe blood flow in the liver caused by
												beta-blockers, and can therefore also occur
												withother drugs in this group. Therefore,
												lercanidipine can be safely co-administered with
												beta-adrenoceptor receptors.blocking drugs, but dose
												adjustment may be necessary.</p>
											<br/>
											<p>Digoxin</p>
											<p>Co-administration of 20 mg lercanidipine to patients
												chronically treated with β-methyldigoxine no
												pharmacokinetic interaction was observed. However,
												one was observedmean increase of 33% of C max for
												digoxin, whereas AUC and renal clearance were
												notsignificantly changed. Patients receiving
												concomitant digoxin treatment should be closely
												monitored forclinical signs of digoxin toxicity.</p>
											<br/>
											<p style="font-weight: bold">Concomitant use with other
												drugs</p>
											<p>Fluoxetine</p>
											<p>An interaction study with fluoxetine (an inhibitor of
												CYP2D6 and CYP3A4), performed involunteers aged 65 ±
												7 years (mean ± sd), showed no clinically relevant
												change inpharmacokinetics of lercanidipine.</p>
											<br/>
											<p>Cimetidine</p>
											<p>Co-administration of a daily dose of cimetidine 800
												mg did not cause any significant changesof
												lercanidipine plasma levels, but caution should be
												exercised at higher doses, asthe bioavailability and
												blood pressure lowering effect of lercanidipine may
												increase.</p>
											<br/>
											<p>Simvastatin</p>
											<p>When a dose of 20 mg lercanidipine was
												co-administered with 40 mg simvastatin
												repeatedly,there were no significant changes in the
												AUC of lercanidipine, but the AUC of simvastatin
												increased by 56%and the active major metabolite of
												simvastatin beta-hydroxy acid increased by 28%. It
												is not likely thatthese changes are clinically
												relevant. No interactions are expected with
												lercanidipineadministered in the morning and
												simvastatin in the evening, as indicated for such a
												drug.</p>
											<br/>
											<p>Diuretics and other ACE inhibitors</p>
											<p>Lercanidipine can be safely administered with
												diuretics and ACE inhibitors.</p>
											<br/>
											<p>Other medicines that affect blood pressure</p>
											<p>As with all antihypertensives, an increased
												hypotensive effect may be observed when
												lercanidipine is administeredtogether with other
												medicines that affect blood pressure, such as alpha
												blockers for the treatment ofurinary tract symptoms,
												tricyclic antidepressants and neuroleptics.</p>
											<br/>
											<p>On the other hand, a reduction in the hypotensive
												effect can be observed with concomitant use
												ofcorticosteroids.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.6 Fertility, pregnancy and lactation -->
									<title value="4.6 Fertility, pregnancy and lactation"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="46"/>
											<display value="fertility"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p style="font-weight: bold">Pregnancy</p>
											<p>There are no data on the use of lercanidipine in
												pregnant women. Animal studies withlercanidipine has
												not shown teratogenic effects (see section 5.3), but
												this has been observed with otherdihydropyridine
												compounds. Lercanidipine is not recommended during
												pregnancy and in women of childbearing potentialage
												not using contraception.</p>
											<br/>
											<p style="font-weight: bold">Breastfeeding</p>
											<p>It is unknown whether lercanidipine / metabolites are
												excreted in human milk. A risk for newborns /
												infants such asbreastfeeding can not be ruled out.
												Lercanidipine should not be used during
												breast-feeding.</p>
											<br/>
											<p style="font-weight: bold">Fertility</p>
											<p>No clinical data are available on lercanidipine.
												Reversible biochemical changes in the head
												ofspermatozoa that can inhibit conception have been
												reported in some patients treated withchannel
												blockers. In cases where repeated in vitro
												fertilization does not succeed and where no other is
												foundexplanation, the possibility that the cause is
												calcium channel blockers should be considered.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.7 Effects on ability to drive and use machines -->
									<title value="4.7 Effects on ability to drive and use machines"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="47"/>
											<display value="effects"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Lercanidipine has little effect on the ability to
												drive or use machines. Care should be takenhowever,
												dizziness, asthenia, fatigue and, in rare cases,
												somnolence may occur.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.8 Side effects -->
									<title value="4.8 Side effects"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="48"/>
											<display value="side effects"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Summary of the security profile</p>
											<p>The safety of lercanidipine at a dose of 10–20 mg
												once daily has been evaluated in the
												double-blind,placebo-controlled clinical trials
												(with 1,200 patients receiving lercanidipine and 603
												patients receivingreceived placebo) and in
												active-controlled and uncontrolled long-term
												clinical trials of a total of 3,676
												hypertensivepatients receiving lercanidipine.</p>
											<br/>
											<p>The most commonly reported adverse reactions in
												clinical trials and post-marketing experience are:
												peripheraledema, headache, flushing, tachycardia and
												palpitations.</p>
											<br/>
											<p>List of side effects in tabular form</p>
											<p>The table below lists the adverse reactions reported
												in clinical trials and experiencemarketing with a
												reasonably probable causal link listed in accordance
												with MedDRAorgan system class and frequency: very
												common (≥ 1/10), common (≥ 1/100 to &lt;1/10),
												uncommon(≥ 1/1000 to &lt;1/100), rare (≥ 1/10 000 to
												&lt;1/1000), very rare (&lt;1/10 000), not known
												(maynot estimated from the available data). Within
												each frequency grouping, adverse reactions are
												observedpresented by decreasing severity.</p>
											<br/>
											<table>
												<thead>
												<tr>
												<th>MedDRA organ class system</th>
												<th>Common</th>
												<th>Less common</th>
												<th>Rare</th>
												<th>Not known</th>
												</tr>
												</thead>
												<tbody>
												<tr>
												<td>Disorders inthe immune system</td>
												<td/>
												<td/>
												<td>hypersensitivity</td>
												<td/>
												</tr>
												<tr>
												<td>Neurologicaldiseases</td>
												<td>headache</td>
												<td>dizziness s somnolence, syncope</td>
												<td/>
												<td/>
												</tr>
												<tr>
												<td>Heart disease</td>
												<td>tachycardia,palpitations</td>
												<td/>
												<td>angina pectoris</td>
												<td/>
												</tr>
												<tr>
												<td>Vascular diseases</td>
												<td>blush</td>
												<td>hypotension</td>
												<td/>
												<td/>
												</tr>
												<tr>
												<td>Gastrointestinaldiseases</td>
												<td/>
												<td>dyspepsia,nausea, pain inupper abdomen</td>
												<td>vomiting, diarrhea</td>
												<td>gingivalhypertrophy <sup>1</sup>,cloudy
												dialysate</td>
												</tr>
												<tr>
												<td>Diseases of the liverand bile ducts</td>
												<td/>
												<td/>
												<td/>
												<td>elevatedtransaminases iserum <sup>1</sup></td>
												</tr>
												<tr>
												<td>Skin andsubcutaneous diseases</td>
												<td/>
												<td>rash,itch</td>
												<td>urticaria</td>
												<td>angioedema <sup>1</sup></td>
												</tr>
												<tr>
												<td>Diseases inmuscles, connective tissue
												andskeleton</td>
												<td/>
												<td>myalgi</td>
												<td/>
												<td/>
												</tr>
												<tr>
												<td>Diseases of the kidney andurinary tract</td>
												<td/>
												<td>polyuria</td>
												<td>pollakiuri</td>
												<td/>
												</tr>
												<tr>
												<td>General disorders andreactions tothe place of
												administration</td>
												<td/>
												<td>peripheral edema asthenia,fatigue</td>
												<td>chest pain</td>
												<td/>
												</tr>
												</tbody>
												<tfoot>
												<tr><sup>1</sup> side effects from spontaneous
												post-marketing reporting from around the
												world</tr>
												</tfoot>
											</table>
											<br/>
											<p>Description of selected adverse reactions</p>
											<p>In placebo-controlled clinical trials, the incidence
												of peripheral edema was 0.9% for lercanidipine 10–20
												mg and 0.83% for placebo. This frequency reached 2%
												in the total study population, includinglong-term
												clinical trials.</p>
											<br/>
											<p>Lercanidipine does not appear to have an adverse
												effect on blood sugar and serum lipid levels.Some
												dihydropyridines can rarely cause precordial pain or
												angina pectoris. Patients withexisting angina
												pectoris can in very rare cases have attacks with
												increased frequency, duration orseverity. Isolated
												cases of myocardial infarction can be observed.</p>
											<br/>
											<p>Reporting of suspected side effects</p>
											<p>Reporting of suspected side effects after approval of
												the drug is important. It makes it possible
												tomonitor the benefit-risk balance of the drug
												continuously. Healthcare professionals are
												encouraged toreport any suspected side effect. This
												is done via the notification form found on the
												website of the StateNorwegian Medicines Agency:
												www.legemiddelverket.no/meldeskjema.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 4.9 Overdose -->
									<title value="4.9 Overdose"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="6"/>
											<display value="Overdose"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>In post-marketing experience with lercanidipine, some
												cases of overdose have been reportedranges from 30
												to 40 mg up to 800 mg, including reports of suicide
												attempts.</p>
											<br/>
											<p>Symptoms</p>
											<p>As with other dihydropyridines, overdose with
												lercanidipine can be expected to cause
												severeperipheral vasodilation with marked
												hypotension and reflex tachycardia. At very high
												doses canhowever, the peripheral selectivity is lost
												and it can cause bradycardia and negative inotropic
												effect.The most common side effects associated with
												overdose are hypotension, dizziness,headaches and
												palpitations.</p>
											<br/>
											<p>Treatment</p>
											<p>Clinically significant hypotension requires active
												cardiovascular measures, e.g. frequent monitoring
												ofcardiac and respiratory function, elevation of
												extremities as well as control of circulating fluid
												volume andexcreted urine volume. Considering the
												prolonged pharmacological effect of lercanidipine,
												wood shouldand ev. overdose, the patient's
												cardiovascular status is monitored for a period of
												at least 24 hours.</p>
											<br/>
											<p>Since the drug has a high protein binding, dialysis
												is in all probability not effective. In
												patientswhere moderate to severe intoxication is
												expected, close monitoring should be instituted.</p>
										</div>
									</text>
								</section>
							</section>
							<section>
								<!-- 5. PHARMACOLOGICAL PROPERTIES -->
								<title value="5. PHARMACOLOGICAL PROPERTIES"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="7"/>
										<display value="pharmaceutical properties"/>
									</coding>
								</code>
								<section>
									<!-- 5.1 Pharmacodynamic properties -->
									<title value="5.1 Pharmacodynamic properties"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="8"/>
											<display value="Pharmacodynamic properties"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Pharmacotherapeutic group: Selective calcium
												antagonists with primary vascular effect
												-Dihydropyridine derivatives.</p>
											<p>ATC code: C08C A13</p>
											<br/>
											<p>Mechanism of action</p>
											<p>Lercanidipine is a calcium antagonist in the
												dihydropyridine group and inhibits the
												transmembranethe influx of calcium into the heart
												muscle and smooth muscle.The mechanism of this
												antihypertensive effect is based on a direct
												relaxing effect onvascular smooth muscle leading to
												reduced total peripheral resistance.</p>
											<br/>
											<p>Pharmacodynamic effects</p>
											<p>Despite its short plasma pharmacokinetic half-life,
												lercanidipine has a prolonged
												durationantihypertensive effect due to its high
												membrane distribution coefficient, and due to
												highvascular selectivity, lercanidipine does not
												have a negative inotropic effect.</p>
											<br/>
											<p>Since vasodilation induced by Zanidip occurs
												gradually, acute hypotension with reflex
												tachycardiararely observed in hypertensive
												patients.</p>
											<br/>
											<p>As with other asymmetric 1,4-dihydropyridines, the
												antihypertensive effect is due tolercanidipine
												mainly its (S) -enantiomer.</p>
											<br/>
											<p>Clinical efficacy and safety</p>
											<p>The clinical efficacy and safety of lercanidipine at
												a dose of 10–20 mg once daily have been evaluated
												indouble-blind, placebo-controlled clinical trials
												(with 1,200 patients receiving lercanidipine and
												603patients receiving placebo) and in
												active-controlled and uncontrolled long-term
												clinical trials of all3,676 hypertensive
												patients.</p>
											<br/>
											<p>Most clinical trials have been performed in patients
												with mild to moderate essential
												hypertension(including elderly and diabetic
												patients) who received lercanidipine alone or in
												combination with ACEinhibitors, diuretics or
												beta-blockers.</p>
											<br/>
											<p>In addition to the clinical studies conducted to
												document the therapeutic indications, areit
												conducted another small, uncontrolled but randomized
												study of patients with severehypertension (mean ± SD
												diastolic blood pressure of 114.5 ± 3.7 mm Hg) which
												showed thatblood pressure was normalized in 40% of
												the 25 patients with a daily dose of 20 mg and in
												56%of 25 patients with two daily doses of 10 mg
												Zanidip. In a double blind, randomized,
												controlledstudy against placebo in patients with
												isolated systolic hypertension Lerkanidipine reduced
												itsystolic pressure from an average initial value of
												172.6 + 5.6 mm Hg to 140.2 + 8.7 mm Hg.</p>
											<br/>
											<p>No clinical studies have been performed in the
												pediatric population.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 5.2 Pharmacokinetic properties -->
									<title value="5.2 Pharmacokinetic properties"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="9"/>
											<display value="Pharmacokinetic properties"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Absorption</p>
											<p>Zanidip is completely absorbed after oral
												administration of 10-20 mg and maximum plasma
												concentrationsat (+ SD) 3.30 + 2.09 ng / ml and 7.66
												+ 5.90 ng / ml, respectively, approx. 1.5-3 hours
												after dosing.</p>
											<br/>
											<p>The two enantiomers of lercanidipine have the same
												plasma profile, time to maximum plasma concentration
												is equaland maximum plasma concentration and AUC are
												approx. 1.2 times higher for the (S) -enantiomer
												andthe half-life of the two enantiomers is the same.
												No in vivo has been observedinterconversion of
												enantiomers.</p>
											<br/>
											<p>Due to the high first-pass metabolism, the absolute
												bioavailability of oraladministered lercanidipine
												about 10% in non-fasting patients, but it is reduced
												to 1/3 when itgiven to healthy fasting
												volunteers.</p>
											<br/>
											<p>The oral availability of lercanidipine quadruples
												when Zanidip is taken up to 2 hours after a high fat
												diet.meal. Zanidip should therefore be taken before
												meals.</p>
											<p>Distribution</p>
											<p>The distribution from plasma to tissues and organs is
												rapid and extensive. The degree of serum protein
												binding exceeds 98%. As plasma protein levels are
												reduced inpatients with severe hepatic or renal
												impairment, the free fraction of the drug may
												increase inthese.</p>
											<br/>
											<p>Biotransformation</p>
											<p>Zanidip is extensively metabolised by CYP3A4; none of
												the parent compound is found in urine or
												faeces.Lercanidipine is mainly converted to inactive
												metabolites and approx. 50% of the dose is excreted
												inthe urine.</p>
											<br/>
											<p>In vitro experiments with human liver microsomes have
												shown that lercanidipine inhibits to some
												extentCYP3A4 and CYP2D6 at concentrations 160 and 40
												times higher, respectively, than the maximumwas
												obtained in plasma after a dose of 20 mg. In
												addition, interaction studies in humans have shown
												thatlercanidipine does not alter plasma levels of
												midazolam, a typical substrate for CYP3A4,
												ormetoprolol, a typical substrate for CYP2D6.
												Therefore, at therapeutic doses of Zanidip will
												notInhibition of the biotransformation of drugs
												metabolised by CYP3A4 and CYP2D6 is expected.</p>
											<br/>
											<p>Elimination</p>
											<p>Elimination occurs mainly through
												biotransformation.The terminal mean elimination
												half-life is estimated at 8-10 hours and theThe
												therapeutic effect lasts for 24 hours due to the
												high binding to lipid membranes. Noaccumulation of
												Zanidip was seen by repeated administration.</p>
											<br/>
											<p>Linearity / non-linearity</p>
											<p>Oral administration of Zanidip results in non-direct
												plasma lercanidipine levelsproportional to the
												dosage (non-linear kinetics). After 10, 20 or 40 mg
												it was observedmaximum concentrations in the ratio
												1: 3: 8 and the area under the curve for plasma
												concentration versus timewas in the ratio 1: 4: 18,
												indicating an increasing saturation of first-pass
												metabolism.Bioavailability therefore increases as
												the dose increases.</p>
											<br/>
											<p>Additional information regarding special
												populations</p>
											<p>In elderly patients and in patients with mild to
												moderate renal or hepatic impairment, showsThe
												pharmacokinetics of lercanidipine do not differ from
												the general patient population. Patients
												withseverely impaired renal function or
												dialysis-dependent patients, show higher levels,
												(approximately 70%) ofthe drug. In patients with
												moderate to severe hepatic impairment, lercanidipine
												will be systemicBioavailability is likely to
												increase, as the preparation is usually extensively
												metabolised in the liver.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 5.3 Preclinical safety data -->
									<title value="5.3 Preclinical safety data"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="10"/>
											<display value="Preclinical safety data"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Non-clinical data reveal no special hazard for humans
												based on conventional studiessafety pharmacology,
												repeated dose toxicity tests, genotoxicity,
												carcinogenic potential andreproductive toxicity.</p>
											<br/>
											<p>Safety pharmacological data from animal experiments
												have shown that there is no effect on itautonomic
												nervous system, central nervous system or
												gastrointestinal function in antihypertensive
												doser.</p>
											<br/>
											<p>The most relevant effects observed in long-term
												studies in rats and dogs were direct or
												indirectrelated to known effects of high doses of
												calcium antagonists, mainly reflected in excessive
												pharmacodynamic activity.</p>
											<br/>
											<p>Lercanidipine shows no evidence of genotoxicity or
												carcinogenic risk.Fertility and general reproductive
												performance in rats were unaffected by treatment
												with lercanidipine. There was no evidence of
												teratogenic effect in rats and rabbits. In rats,
												lercanidipine in ihigh doses, however, pre- and
												post-implantation loss and delay in fetal
												development.</p>
											<br/>
											<p>Lercanidipine hydrochloride given in high doses (12
												mg / kg / day) during labor pains gave rise to
												dystocia.Distribution of lercanidipine and / or its
												metabolites in pregnant animals and their excretion
												in human milkhas not been investigated.</p>
											<br/>
											<p>Metabolites have not been evaluated separately in
												toxicity studies.</p>
										</div>
									</text>
								</section>
							</section>
							<section>
								<!-- 6. PHARMACEUTICAL PARTICULARS -->
								<title value="6. PHARMACEUTICAL PARTICULARS"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="6"/>
										<display value="PHARMACEUTICAL PARTICULARS"/>
									</coding>
								</code>
								<section>
									<!-- 6.1 List of excipients -->
									<title value="6.1 List of excipients"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="61"/>
											<display value="List of excipients"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Tablet core:</p>
											<p>Lactose monohydrate</p>
											<p>Sodium glycolate starch</p>
											<p>Povidone K30</p>
											<p>Magnesium stearate</p>
											<p>Cellulose, microcrystalline</p>
											<br/>
											<p>Film coating:</p>
											<p>Hypromellose</p>
											<p>Titanium dioxide (E171)</p>
											<p>Macrogol 6000</p>
											<p>Iron oxide (E172)</p>
											<p>Talkum</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 6.2 Incompatibilities -->
									<title value="6.2 Incompatibilities"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="62"/>
											<display value="Incompatibilities"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Not relevant</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 6.3 Durability -->
									<title value="6.3 Durability"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="63"/>
											<display value="Durability"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>3 years</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 6.4 Special precautions for storage -->
									<title value="6.4 Special precautions for storage"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="64"/>
											<display value="Special precautions for storage"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Store in the original package in order to protect
												from light.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 6.5 Nature and contents of container -->
									<title value="6.5 Nature and contents of container"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="65"/>
											<display value="Nature and contents of container"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>PVC / aluminum blister board</p>
											<p>Pack sizes: 28, 56 and 98 tablets*</p>
											<p>* Not all pack sizes may be marketed.</p>
										</div>
									</text>
								</section>
								<section>
									<!-- 6.6 Special precautions for disposal -->
									<title value="6.6 Special precautions for disposal"/>
									<code>
										<coding>
											<system
												value="http://spor.ema.europa.eu/v1/example-sections"/>
											<code value="66"/>
											<display value="6.6 Special precautions for disposal"/>
										</coding>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>Any unused product or waste material should be
												disposed of in accordance with local
												requirements.</p>
										</div>
									</text>
								</section>
							</section>
							<section>
								<!-- 7. HOLDER OF THE MARKETING AUTHORIZATION -->
								<title value="7. HOLDER OF THE MARKETING AUTHORIZATION"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="7"/>
										<display value="HOLDER OF THE MARKETING AUTHORIZATION"/>
									</coding>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<p>Meda AS</p>
										<p>PO Box 194</p>
										<p>1371 Asker</p>
									</div>
								</text>
							</section>
							<section>
								<!-- 8. MARKETING AUTHORIZATION NUMBER(S) -->
								<title value="8. MARKETING AUTHORIZATION NUMBER(S)"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="8"/>
										<display value="MARKETING AUTHORIZATION NUMBER(S)"/>
									</coding>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<p>98-6653</p>
									</div>
								</text>
							</section>
							<section>
								<!-- 9. DATE OF FIRST MARKETING AUTHORIZATION / LAST RENEWAL -->
								<title
									value="9. DATE OF FIRST MARKETING AUTHORIZATION / LAST RENEWAL"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="9"/>
										<display
											value="DATE OF FIRST MARKETING AUTHORIZATION / LAST RENEWAL"
										/>
									</coding>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<p>Date of first marketing authorization: 05 May 2000</p>
										<p>Date of last renewal: July 3, 2008</p>
									</div>
								</text>
							</section>
							<section>
								<!-- 10. UPDATE DATE -->
								<title value="10. UPDATE DATE"/>
								<code>
									<coding>
										<system
											value="http://spor.ema.europa.eu/v1/example-sections"/>
										<code value="10"/>
										<display value="UPDATE DATE"/>
									</coding>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<p>02/14/2019</p>
									</div>
								</text>
							</section>
						</Composition>
					</resource>
				</entry>
				<!-- an entry that is a list of PMS Product references -->
				<entry>
					<fullUrl value="urn:uuid:548506e8-130d-40c4-8979-6177c0a96a66"/>
					<resource>
						<List>
							<!-- any id will do -->
							<!--id value="${instance.bundle[n].listId}"/-->
							<status value="current"/>
							<mode value="working"/>
							<entry>
								<!-- Product 1 Zandip 10 mg-->
								<item>
									<reference value="MedicinalProductDefinition/Zandip10"/>
									<display value="Zandip 10 mg tablets"/>
								</item>
							</entry>
							<entry>
								<!-- Product 2 Zandip 20 mg -->
								<item>
									<reference value="MedicinalProductDefinition/Zandip20"/>
									<display value="Zandip 20 mg tablets"/>
								</item>
							</entry>
						</List>
					</resource>
				</entry>
			</Bundle>
		</resource>
		<request>
			<method value="POST"/>
			<url value="Bundle"/>
		</request>
	</entry>
</Bundle>
